GeRmLIne+
Genetic Testing for Hereditary Cancers with HRD (deficient HRR) gene analysis
Germline + uses Next-Generation Sequencing (NGS) based Genetic Testing for Hereditary and Familial Cancers that are caused by deficient DDR (DNA Damage Repair) and HRR (Homologous Recombination Repair) genes.
Germline+ analyzes 213 genes (as per ACMG/NCCN/ESMO/AMP/CAP/FDA recommendations) that are associated with increased cancer risk in different hereditary and familial cancers.
Germline + panel offers important value addition to the patient by the inclusion of HRR (36 genes including BRCA1 & BRCA2) pathway genes which are predictive biomarkers for PARP inhibitor therapy.
How Germline+ Testing Can Impact Patients?
Hereditary cancer risk assessment– Predicts cancer risk if you/your family members have a deleterious mutation
Informed decision making – To aid in the informed treatment plan
Disease prognostication – Impact on the overall survival rate of cancer patients
Lifecycle cost saving – Early diagnosis reduces the cost of treatment
Consult our Genetic Counselor to find the right test for you.
Kindly fill the form below to download our